Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2026-526903-31-00
Authorised, not yet recruiting Phase II

Èn dosis intravenøs penicillin som tillæg til peroral penicillin i behandlingen af akut tonsillitis, peritonsillær phlegmone og peritonsillær absces – et randomiseret, dobbeltblindet, placebo-kontrolleret studie

2026-526903-31-00 · tracked via the Priya Life Science EU tracker
Sponsor
Region Midtjylland
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Bacterial Infections and Mycoses
Decision date
21/08/2026
Enrollment target
154
Sites
Denmark

Condition studied

Tonsillitis

Investigational medicinal product(s)

BENZYLPENICILLINNaCl 0,9 % B. BraunInjektionslösung

Every trial of Benzylpenicillin across our registers →

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

STAT-10 score on Day 2 (for AT and PP) and PTAAT-12 score on Day 2 (for PTA), Time to symptom resolution

Endpoint detail

VAS pain score on Day 2. Total analgesic consumption during Days 1–7. Cumulative PTAAT-12 score during Days 1–7. Complications within 14 days. TOI-14 score at 6 and 12 months. Proportion of patients undergoing tonsillectomy at 6 and 12 months. Number of episodes of AT, PP, or PTA at 6 and 12 months., Estimated MCID for STAT-10 and estimated MCID for PTAAT-12

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526903-31-00 on CTIS ↗ ← All trials in the EU